Max Planck Innovation awards license for actin marker LifeAct
Max Planck Innovation and ibidi sign license agreement for cytoskeleton research
28-Jul-2010 -
Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, has awarded an exclusive license for LifeAct to ibidi GmbH, a provider of cell analysis products, located in Martinsried near Munich. The novel peptide allows for actin, an important protein, to be made ...
amino acids
angiogenesis
Bio-Medical Research
+16